MHRA authorises oral semaglutide (Wegovy tablet): first peptide GLP-1 tablet licensed for weight management in the UK

On 11 June 2026 the Medicines and Healthcare products Regulatory Agency (MHRA) authorised a once-daily oral tablet of semaglutide, to be marketed in the UK as Wegovy, for weight loss and weight management in specified adults. The Agency described it as the United Kingdom’s first glucagon-like peptide-1 (GLP-1) receptor agonist tablet licensed for that indication. Novo Nordisk, the marketing-authorisation holder, stated that the MHRA is the third regulator to license the tablet, after the US Food and Drug Administration and the United Arab Emirates’ Emirates Drug Establishment, and the first in Europe.

This is a news record of a licensing decision. It is not consumption, dosing, or self-administration advice. Peptide Data does not claim that semaglutide, or any other GLP-1 receptor agonist, treats, cures, or prevents any condition.

The tablet is a peptide — the same active substance as injectable Wegovy and Ozempic, formulated with the absorption enhancer sodium N-[8-(2-hydroxybenzoyl) amino] caprylate (SNAC). That distinguishes it from orforglipron (Foundayo), the non-peptide oral GLP-1 receptor agonist the MHRA authorised two months later, on 10 August 2026. A lower-dose oral semaglutide tablet (Rybelsus) was already licensed in the UK for type 2 diabetes; this authorisation is a new weight-management indication at a higher licensed strength.

1. What the MHRA authorised

Authorisation for the new indication was granted to Novo Nordisk on 11 June 2026. Alongside a reduced-calorie diet and increased physical activity, the tablet may be prescribed to adults with a body-mass index (BMI) of 30 kg/m² or above, or a BMI between 27 and 30 kg/m² with at least one weight-related comorbidity.

The marketing authorisation specifies a titration sequence beginning at 1.5 mg once daily and escalating through 4 mg and 9 mg to a 25 mg tablet, with a minimum of one month at each dose level. Those strengths are the licensed UK posology. They are not a protocol for unlicensed research use, and they are not interchangeable with the 3 mg, 7 mg and 14 mg strengths of Rybelsus or with the 50 mg dose evaluated in OASIS 1.

The Agency also stated that adults already treated privately with a 2.4 mg once-weekly semaglutide injection may be switched directly to the 25 mg tablet under the licence. That is a statement about the authorised product, not a recommendation for any other formulation or supply channel.

Julian Beach, MHRA Executive Director of Healthcare Quality and Access, said the Agency had completed a rigorous assessment of safety, quality and effectiveness, and that “as with all GLP-1 receptor agonists, this is a prescription-only medication.”

The most common adverse reactions listed by the MHRA are gastrointestinal disorders, including nausea, diarrhoea, constipation and vomiting. The Agency said the summary of product characteristics and patient information leaflet would be published on the MHRA Products website within seven days of approval, and that it will keep the safety of semaglutide under review through the Yellow Card scheme.

The licensed tablet is taken whole after an overnight fast of at least eight hours, with a sip of water; food or drink within 30 minutes reduces absorption. Those conditions are pharmacokinetic constraints of SNAC-enabled oral peptide delivery. They are not research-use instructions.

2. Legal status in the United Kingdom

Oral semaglutide for this indication is a prescription-only medicine (POM) under the Human Medicines Regulations 2012. Supply otherwise than in accordance with a valid prescription issued by an appropriate practitioner is an offence. The MHRA has restated, for the GLP-1 class as a whole, that these medicines can be obtained only from a registered pharmacy against a prescription, that buying them from unregulated sellers carries serious health risks, and that it is unlawful to advertise a POM to the public.

A marketing authorisation is not an NHS commissioning decision. The MHRA states that the tablet is not currently available via the NHS and that decisions on NHS use will follow established processes, including evaluation by the National Institute for Health and Care Excellence (NICE). Until that appraisal concludes, and until any subsequent NHS commissioning takes effect, the licensed product is not a routinely funded NHS medicine. Injectable semaglutide (Wegovy) already has a separate NICE recommendation (TA875) for a narrower specialist-service population; that recommendation does not automatically extend to the oral tablet.

The authorisation does not reclassify unlicensed research peptides, does not create a general retail market in GLP-1 receptor agonists, and does not authorise compounding or research-chemical supply of semaglutide.

Under the Medicines Act 1968 and the Human Medicines Regulations 2012, a substance presented for the treatment or prevention of disease, or administered with a view to modifying a physiological function, is a medicinal product. Labelling a vial or tablet “for research only” does not displace that analysis where the circumstances of supply point to human administration. Peptide Data’s compound profiles continue to treat unlicensed peptides as research compounds, not as alternatives to licensed POMs.

3. Evidence underlying the licence: OASIS 4

The weight-management indication is supported by OASIS 4, a 64-week, Phase 3, randomised, double-blind, placebo-controlled trial of once-daily oral semaglutide 25 mg in 307 adults with obesity, or overweight plus at least one weight-related comorbidity, and without type 2 diabetes. Participants were randomised 2:1 to oral semaglutide or placebo and received lifestyle advice, including a daily 500 kcal deficit. Results were published in the New England Journal of Medicine on 17 September 2025.

Two pre-specified estimands were reported. The treatment-policy estimand estimates the effect regardless of discontinuation and is the more conservative figure for regulatory reading. The on-treatment estimand estimates the effect if all participants had adhered to the assigned regimen.

Mean percent change in body weight at 64 weeks, as reported by the marketing-authorisation holder:

treatment-policy estimand: −13.6% with oral semaglutide 25 mg versus −2.4% with placebo
on-treatment estimand: −16.6% versus −2.7%

The published trial reported that the primary endpoint of estimated mean change in body weight at week 64 was significantly greater with oral semaglutide than with placebo (p < 0.001). Body-weight reductions of at least 5%, 10%, 15% and 20% were all more frequent with oral semaglutide; about 30% of participants assigned to 25 mg lost at least 20% of body weight, compared with 3% on placebo. Physical-function scores on the IWQOL-Lite-CT instrument also improved relative to placebo.

The trial population was 79% women and 92% White, with a mean age of 48 years. Those demographics limit how far the point estimates can be generalised. OASIS 4 excluded people with type 2 diabetes; it is not evidence for a diabetes indication, and it is not a head-to-head comparison with once-weekly injectable semaglutide 2.4 mg (STEP 1) or with oral semaglutide 50 mg (OASIS 1).

Gastrointestinal adverse events were the dominant tolerability finding, reported in 74.0% of participants on oral semaglutide and 42.2% on placebo, and were generally described as mild to moderate and transient. Adverse events leading to discontinuation occurred in 6.9% of the oral-semaglutide group, a rate the sponsor described as consistent with injectable semaglutide trials.

These figures describe a randomised trial population under protocol conditions. They are not forecasts of individual outcome and they are not a basis for unlicensed use.

4. How this sits next to injectable Wegovy and orforglipron

The active substance is semaglutide in both the weekly injection and the daily tablet. The licensed oral strengths, the SNAC-dependent fasting conditions, and the OASIS 4 population are not the same as the STEP programme that supported injectable Wegovy. Cross-trial arithmetic between OASIS 4 and STEP 1 is not evidence of relative efficacy.

An earlier Peptide Data article recorded the US Food and Drug Administration’s December 2025 approval of the same oral formulation. That is a different jurisdiction. The 11 June decision is the UK marketing authorisation.

Two months later, on 10 August 2026, the MHRA authorised orforglipron (Foundayo), a once-daily non-peptide GLP-1 receptor agonist with no food or water restrictions. The two licences should not be read as a head-to-head comparison. OASIS 4 and ATTAIN-1 enrolled different populations, ran for different durations (64 versus 72 weeks), and used different estimands and dose constructs. What can be stated is narrower: as of August 2026 the UK has two authorised oral GLP-1 receptor agonist tablets, only one of which is a peptide, and neither is commissioned on the NHS pending NICE.

5. Safety signals already on the UK record

The MHRA continues to apply class-level GLP-1 warnings to authorised products in this group, including acute pancreatitis (including necrotising and fatal cases) and pulmonary aspiration risk before anaesthesia or deep sedation. For semaglutide specifically, the Agency has already added precautions for a very rare risk of non-arteritic anterior ischaemic optic neuropathy (NAION). Those signals are documented in existing Peptide Data safety articles. Whether every class warning is reproduced verbatim on the oral Wegovy summary of product characteristics will be clear once that document is published on the MHRA Products website.

6. What this does not change for research peptides

A marketing authorisation for a finished medicinal product is not a licence to possess, compound, or supply unlicensed peptides for human use. Semaglutide remains a POM when supplied as a licensed medicine, whether as Ozempic, Rybelsus, injectable Wegovy, or this tablet. Research-chemical listings that invoke the semaglutide name, or that offer “research-use” oral GLP-1 tablets, are not covered by this authorisation.

7. What to watch next

Three items will determine how much this licence matters in UK practice.

First, the Wegovy tablet SmPC. Until it is on the MHRA Products register, the licensed posology, contraindications and class-warning language should be read from the 11 June notice rather than from US prescribing information or from the OASIS 4 protocol.

Second, NICE. No publication date for an oral-semaglutide weight-management appraisal had been confirmed at the time of writing. A positive recommendation would still leave commissioning, service capacity and eligibility criteria to be settled, as they were after TA875 (injectable semaglutide) and TA1026 (tirzepatide).

Third, supply-chain integrity. The MHRA has already issued a drug-safety update on falsified Mounjaro (tirzepatide) 15 mg KwikPens in 2026. An oral tablet is a different presentation with a different counterfeit profile. Any Yellow Card cluster or falsified-product alert will be material.

Until those three items move, the accurate statement is limited: oral semaglutide 25 mg is now a UK-licensed POM for a defined weight-management indication; it is not an NHS medicine; it does not reclassify unlicensed research peptides; and it does not authorise compounding or research-chemical supply of semaglutide.

This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.